These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 35073576)

  • 1. Methods to Correct Drug-Induced Coagulopathy in Bleeding Emergencies: A Comparative Review.
    Nalezinski S
    Lab Med; 2022 Jul; 53(4):336-343. PubMed ID: 35073576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
    Scaglione F
    Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
    Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring and reversal strategies for new oral anticoagulants.
    Vanden Daelen S; Peetermans M; Vanassche T; Verhamme P; Vandermeulen E
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):95-103. PubMed ID: 25431993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing a management plan for oral anticoagulant reversal.
    Dager WE
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S21-31. PubMed ID: 23640529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
    Ansell JE
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):163-70. PubMed ID: 26872887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic interventions for reversing the effects of oral anticoagulants.
    Kalus JS
    Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G; Albaladejo P; Godier A; Samama CM; Susen S; Gruel Y; Blais N; Fontana P; Cohen A; Llau JV; Rosencher N; Schved JF; de Maistre E; Samama MM; Mismetti P; Sié P;
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.
    Gibler WB; Racadio JM; Hirsch AL; Roat TW
    Crit Pathw Cardiol; 2019 Sep; 18(3):143-166. PubMed ID: 31348075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of anticoagulants: an overview of current developments.
    Greinacher A; Thiele T; Selleng K
    Thromb Haemost; 2015 May; 113(5):931-42. PubMed ID: 25832311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.